<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>SGLTL</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">SGLTL</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="standard-glass-lining-technology-limited" class="section level1">
<h1>Standard Glass Lining Technology Limited</h1>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SGLTL.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SGLTL.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SGLTL.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SGLTL.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SGLTL.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SGLTL.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SGLTL.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SGLTL.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<div id="comprehensive-analysis-of-standard-glass-lining-technology-limited-sgltl-listed-on-bse-nse-symbol-sgltl-scrip-544333" class="section level9">
<p class="heading"><strong>Comprehensive Analysis of Standard Glass Lining Technology Limited (SGLTL) ‚Äì Listed on BSE &amp; NSE (Symbol: SGLTL, Scrip: 544333)</strong></p>
<hr />
</div>
<div id="executive-summary" class="section level6">
<h6><strong>Executive Summary</strong></h6>
<p>Standard Glass Lining Technology Limited (SGLTL) is undergoing a <strong>strategic transformation</strong> from a niche manufacturer of <strong>glass-lined reactors</strong> into a <strong>full-stack, precision engineering solutions provider</strong> serving the pharmaceutical, chemical, biotechnology, food &amp; beverage, and allied process industries. The company‚Äôs financial performance, strategic acquisitions, and corporate restructuring signal its ambitions to become a <strong>global end-to-end ‚Äúconcept-to-commissioning‚Äù engineering player</strong>.</p>
<p>Using disclosures made under SEBI LODR, including financial results, management commentary, and transaction updates as of November 2025, this analysis evaluates <strong>tailwinds, headwinds, growth prospects, and key risks</strong> for SGLTL.</p>
<hr />
</div>
<div id="financial-performance-solid-revenue-growth-with-slight-margin-pressure" class="section level6">
<h6><strong>1. Financial Performance: Solid Revenue Growth with Slight Margin Pressure</strong></h6>
<div id="key-figures-unaudited-h1-fy26-quarter-ended-september-2025" class="section level9">
<p class="heading"><strong>Key Figures (Unaudited ‚Äì H1 FY26, Quarter Ended September 2025)</strong></p>
<table>
<colgroup>
<col width="10%" />
<col width="11%" />
<col width="11%" />
<col width="20%" />
<col width="11%" />
<col width="11%" />
<col width="20%" />
</colgroup>
<thead>
<tr class="header">
<th>Metric</th>
<th>H1 FY26</th>
<th>H1 FY25</th>
<th>% Change YoY</th>
<th>Q2 FY26</th>
<th>Q1 FY26</th>
<th>% Change QoQ</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Consolidated Revenue</td>
<td>‚Çπ36,638 Cr</td>
<td>‚Çπ31,210 Cr</td>
<td><strong>+17.4% YoY</strong></td>
<td>‚Çπ18,820 Cr</td>
<td>‚Çπ17,817 Cr</td>
<td><strong>+5.6% QoQ</strong></td>
</tr>
<tr class="even">
<td>PAT (Attributable)</td>
<td>‚Çπ41.58 Cr</td>
<td>‚Çπ3,626 Cr</td>
<td><strong>+14.6% YoY</strong></td>
<td>‚Çπ20.45 Cr</td>
<td>‚Çπ21.13 Cr</td>
<td><strong>-3.2% QoQ</strong></td>
</tr>
<tr class="odd">
<td>EBITDA</td>
<td>‚Çπ690.5 Cr</td>
<td>‚Çπ630.8 Cr</td>
<td><strong>+9.5% YoY</strong> (calculated from OPBT and D&amp;A)</td>
<td>‚Çπ340 Cr (Press Release)</td>
<td>~‚Çπ350 Cr</td>
<td><strong>-2.9% QoQ</strong> approx</td>
</tr>
<tr class="even">
<td>EPS (Basic) ‚Äì H1</td>
<td>‚Çπ2.06</td>
<td>‚Çπ1.89</td>
<td><strong>+9% YoY</strong></td>
<td>‚Çπ1.01</td>
<td>‚Çπ1.05</td>
<td><strong>-3.8% QoQ</strong></td>
</tr>
</tbody>
</table>
<blockquote>
<p><em>Note: Figures in lakhs (‚Çπ000,000); data derived from standalone &amp; consolidated statements and press release.</em></p>
</blockquote>
</div>
<div id="interpretation" class="section level9">
<p class="heading"><strong>Interpretation</strong></p>
<ul>
<li><strong>Strong top-line momentum</strong> driven by domestic demand and export pipeline.</li>
<li><strong>PAT growth lags revenue growth</strong>, suggesting <strong>margin compression</strong> ‚Äì possibly due to higher interest costs or integration expenses.</li>
<li><strong>Sequential decline in Q2 PAT &amp; EBITDA</strong> despite revenue growth, indicating <strong>working capital pressure or one-time costs</strong>.</li>
<li><strong>Working capital cycles under stress</strong>:
<ul>
<li>Trade receivables increased by <strong>‚Çπ198 Cr</strong> QoQ (from ‚Çπ21,402 Cr to ‚Çπ23,578 Cr).<br />
</li>
<li>Inventory up by <strong>‚Çπ8,426 Cr</strong> in H1 FY26 ‚Üí may point to long project cycles or unsynchronized supply-demand.</li>
</ul></li>
</ul>
<hr />
</div>
</div>
<div id="tailwinds-growth-catalysts-strategic-advantages" class="section level6">
<h6><strong>2. Tailwinds: Growth Catalysts &amp; Strategic Advantages</strong></h6>
<div id="a.-transformative-acquisitions-vertical-horizontal-integration" class="section level9">
<p class="heading"><strong>A. Transformative Acquisitions ‚Äì Vertical &amp; Horizontal Integration</strong></p>
<ol style="list-style-type: decimal">
<li><strong>Acquisition of Scigenics (India) Pvt Ltd (‚Çπ9 Cr) via Standard Scigenics Pvt Ltd (subsidiary)</strong>
<ul>
<li>Adds <strong>bioprocess, fermentation, and high-purity equipment capability</strong>.<br />
</li>
<li>Enhances positioning in the <strong>booming biotech &amp; life sciences sector</strong>.<br />
</li>
<li>Strategic entry into <strong>high-margin niche products</strong>.</li>
</ul></li>
<li><strong>Proposed Acquisition of C2C Engineering Pvt Ltd (51%, binding Term Sheet signed, SPA executed on Nov 14, 2025)</strong>
<ul>
<li>Adds <strong>engineering, design, and EPC (Engineering, Procurement, Construction)</strong> capabilities.<br />
</li>
<li>Enables <strong>‚ÄúConcept-to-Commissioning‚Äù</strong> model ‚Äì a rare integrated offering in Indian engineering space.<br />
</li>
<li>Cross-selling potential across existing client base (pharma, chemicals, food, tyres, paints).</li>
</ul></li>
</ol>
<blockquote>
<p>With these moves, SGLTL evolves from <strong>component manufacturer</strong> to <strong>turnkey solutions provider</strong>, commanding <strong>higher project values, better margins, and longer client stickiness</strong>.</p>
</blockquote>
<hr />
</div>
<div id="b.-diversified-product-portfolio-expansion-into-new-markets" class="section level9">
<p class="heading"><strong>B. Diversified Product Portfolio &amp; Expansion into New Markets</strong></p>
<ul>
<li><strong>Segment Revenue (H1 FY26, Consolidated):</strong>
<ul>
<li><strong>Glass-Lined Equipment</strong>: ‚Çπ12,003 Cr (33% of total)<br />
</li>
<li><strong>Metal Equipment &amp; Pumps</strong>: ‚Çπ24,044 Cr (<strong>66%</strong>) ‚Üí Emerging as core revenue driver<br />
</li>
<li><strong>PTFE-Lined Equipment</strong>: ‚Çπ1,566 Cr ‚Üí High-margin specialty segment</li>
</ul></li>
<li><strong>Transition Beyond Glass-Lining:</strong>
<ul>
<li>Company proposes <strong>name change to <em>Standard Engineering Technology Ltd</em></strong> ‚Äì symbolic of <strong>strategic diversification</strong>.<br />
</li>
<li>Maintains leadership in core glass-lining while scaling <strong>non-glass product lines</strong>.</li>
</ul></li>
</ul>
<hr />
</div>
<div id="c.-strong-domestic-and-export-demand" class="section level9">
<p class="heading"><strong>C. Strong Domestic and Export Demand</strong></p>
<ul>
<li><strong>Strong domestic orders</strong> in pharma and chemical sectors.</li>
<li><strong>Export pipeline remains robust</strong> (‚Çπ40‚Äì45 Cr postponed to Q3‚ÄìQ4 FY26) ‚Üí <strong>pull-forward of revenue</strong> expected in upcoming quarters.</li>
<li><strong>High inquiry levels in biotech and food processing</strong> post-Scigenics integration ‚Üí indicative of <strong>successful cross-selling</strong>.</li>
</ul>
<hr />
</div>
<div id="d.-successful-ipo-and-prudent-fund-utilization" class="section level9">
<p class="heading"><strong>D. Successful IPO and Prudent Fund Utilization</strong></p>
<ul>
<li><strong>IPO in Jan 2025</strong>, raising ‚Çπ23,224.5 Cr (net).<br />
</li>
<li><strong>Fund Utilization (as of Sept 30, 2025):</strong><br />
| Purpose | Allocated (‚Çπ Cr) | Utilized (‚Çπ Cr) | Status | |‚Äî‚Äî‚Äì|‚Äî‚Äî‚Äî‚Äî‚Äî‚Äî|‚Äî‚Äî‚Äî‚Äî‚Äî-|‚Äî‚Äî‚Äì| | Repay debt | 13,000 | 13,000 | Completed | | Capex (Parent) | 1,000 | 95.5 | Underutilized | | Capex (S2 Engineering) | 3,000 | 680.7 | Underutilized | | Inorganic Growth | 2,000 | 0 | Pending (aligned with C2C acquisition) | | General Corporate | 4,224.5 | 0 | Unutilized |</li>
</ul>
<blockquote>
<p><strong>‚Çπ9,448 Cr of IPO proceeds remain unutilized</strong>, invested in <strong>term deposits</strong>.<br />
High cash balance supports <strong>acquisitions, capex, and organic growth</strong> ‚Äì significant <strong>optionality</strong>.</p>
</blockquote>
<hr />
</div>
</div>
<div id="headwinds-challenges" class="section level6">
<h6><strong>3. Headwinds &amp; Challenges</strong></h6>
<div id="a.-margin-pressure-in-q2-fy26" class="section level9">
<p class="heading"><strong>A. Margin Pressure in Q2 FY26</strong></p>
<ul>
<li>While revenue grew QoQ, <strong>PAT declined</strong>.<br />
</li>
<li>Possible drivers:
<ul>
<li><strong>Higher interest costs</strong>: Finance cost up to ‚Çπ501 Cr in H1 (from ‚Çπ334 Cr in H1 FY25) due to increased borrowings post-acquisition.<br />
</li>
<li>Integration costs from Scigenics acquisition.</li>
<li>Export delays may have disrupted production schedules, increasing idle cost burden.</li>
</ul></li>
</ul>
<blockquote>
<p><strong>Interest Coverage Ratio (EBITDA / Finance Cost): ~2.7x</strong> ‚Üí raises concern over <strong>leverage sustainability</strong> if interest rates rise.</p>
</blockquote>
<hr />
</div>
<div id="b.-ipo-proceeds-utilization-lags-behind-expectations" class="section level9">
<p class="heading"><strong>B. IPO Proceeds Utilization Lags Behind Expectations</strong></p>
<ul>
<li>Only <strong>~60% of IPO funds deployed</strong> in 10 months.<br />
</li>
<li>Minimal progress on capex and general corporate purposes.</li>
<li><strong>Shareholders may question pace of capital deployment</strong>, expecting faster value creation.</li>
</ul>
<hr />
</div>
<div id="c.-working-capital-constraints" class="section level9">
<p class="heading"><strong>C. Working Capital Constraints</strong></p>
<ul>
<li><strong>Trade Receivables</strong>: ‚Çπ23,578 Cr (up ‚Çπ2,176 Cr H1 FY26)<br />
</li>
<li><strong>Inventories</strong>: ‚Çπ36,356 Cr (up ‚Çπ8,426 Cr)<br />
</li>
<li>vs.¬†<strong>Cash &amp; Equivalents</strong>: ‚Çπ327 Cr</li>
</ul>
<blockquote>
<p>Despite strong sales, <strong>cash generation weak</strong>:<br />
- <strong>Operating cash flow (H1 FY26)</strong>: ‚Çπ(410) Cr (outflow)<br />
- Prior year: ‚Çπ(1,934) Cr (much worse)<br />
- Improvement due to payables growth, but still negative</p>
</blockquote>
<blockquote>
<p><strong>Liquidity risk exists</strong> ‚Äì company relies on <strong>working capital financing</strong> and internal cash build-up.</p>
</blockquote>
<hr />
</div>
</div>
<div id="growth-prospects-high-conviction-for-long-term-outperformance" class="section level6">
<h6><strong>4. Growth Prospects: High Conviction for Long-Term Outperformance</strong></h6>
<table>
<colgroup>
<col width="46%" />
<col width="53%" />
</colgroup>
<thead>
<tr class="header">
<th>Driver</th>
<th>Outlook</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Turnkey Solutions Expansion</strong></td>
<td>With C2C, SGLTL can bid for <strong>larger EPC contracts</strong> (‚Çπ100+ Cr per project), significantly increasing <strong>ticket size</strong></td>
</tr>
<tr class="even">
<td><strong>Biotech &amp; Pharma Capex Boom</strong></td>
<td>India‚Äôs push for <strong>Atmanirbhar Bharat in pharma supplies</strong> benefits SGLTL‚Äôs core customers</td>
</tr>
<tr class="odd">
<td><strong>Export Scalability</strong></td>
<td>Postponed ‚Çπ45 Cr exports + new global inquiries ‚Üí <strong>strong visibility into FY26 H2</strong></td>
</tr>
<tr class="even">
<td><strong>Cross-Sell to Scigenics Clients</strong></td>
<td>High-value <strong>fermentation systems, clean utilities</strong> add premium product offerings</td>
</tr>
<tr class="odd">
<td><strong>Scalable Business Model</strong></td>
<td>Transition to <strong>solutions model</strong> offers <strong>recurring revenue from service &amp; validation</strong></td>
</tr>
</tbody>
</table>
<blockquote>
<p><strong>Target TAM</strong>: Could expand from <strong>chemical/pharma reactors</strong> (‚àº‚Çπ5,000 Cr) to <strong>full process equipment &amp; EPC</strong> (‚àº‚Çπ30,000+ Cr in India), unlocking <strong>5‚Äì6x market potential</strong>.</p>
</blockquote>
<hr />
</div>
<div id="key-risks-watchouts" class="section level6">
<h6><strong>5. Key Risks &amp; Watchouts</strong></h6>
<table>
<colgroup>
<col width="31%" />
<col width="68%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>1. Acquisitions Integration Risk</strong></td>
<td>Success of Scigenics &amp; C2C depends on <strong>cultural alignment, client retention, and cost integration</strong>. Poor execution could erode margins.</td>
</tr>
<tr class="even">
<td><strong>2. Leveraged Balance Sheet</strong></td>
<td><strong>Net Debt/Equity likely rising</strong> post-acquisitions. Monitoring <strong>interest coverage and total debt</strong> is critical.</td>
</tr>
<tr class="odd">
<td><strong>3. Dependency on Large Projects</strong></td>
<td>Turnkey projects are <strong>lumpy, long-cycle</strong>, with <strong>working capital locks</strong>. Sales may be uneven, causing quarterly volatility.</td>
</tr>
<tr class="even">
<td><strong>4. Regulatory &amp; Shareholder Approvals Delaying C2C Deal</strong></td>
<td>Acquisition depends on approvals. Any delay or failure may <strong>disrupt strategic synergy plans</strong>.</td>
</tr>
<tr class="odd">
<td><strong>5. Execution in New Segments</strong></td>
<td>Scaling into <strong>food, tyres, paints</strong> ‚Äì markets with different standards ‚Äì poses a <strong>learning curve</strong> and execution risk.</td>
</tr>
<tr class="even">
<td><strong>6. Export Concentration &amp; Geopolitical Risk</strong></td>
<td>Exposure to <strong>global pharma supply chains</strong> makes it vulnerable to <strong>trade barriers or client defaults overseas</strong>.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="strategic-indicators-forward-looking-signals" class="section level6">
<h6><strong>6. Strategic Indicators &amp; Forward-Looking Signals</strong></h6>
<table>
<thead>
<tr class="header">
<th>Signal</th>
<th>Current Status</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Name Change Proposal</strong></td>
<td>Board approved</td>
</tr>
<tr class="even">
<td><strong>ESOP Expansion</strong></td>
<td>Proposed for <strong>subsidiary &amp; associate employees</strong></td>
</tr>
<tr class="odd">
<td><strong>Postal Ballot Scheduled</strong></td>
<td>Record date: Nov 7, 2025</td>
</tr>
<tr class="even">
<td><strong>Analyst Day Scheduled</strong></td>
<td>Dec 2, 2025, Mumbai</td>
</tr>
<tr class="odd">
<td><strong>Cash Position</strong></td>
<td>~‚Çπ327 Cr cash + ‚Çπ9,448 Cr IPO proceeds in deposits</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="conclusion-buy-the-transformation-story-with-caution" class="section level6">
<h6><strong>Conclusion: Buy the Transformation Story with Caution</strong></h6>
<div id="investment-thesis-bull-case" class="section level9">
<p class="heading">‚úÖ <strong>Investment Thesis (Bull Case):</strong></p>
<blockquote>
<p><strong>SGLTL is transitioning from a ‚Çπ2,000 Cr glass-lining player to a ‚Çπ5,000+ Cr integrated engineering champion</strong>. With the Scigenics acquisition providing <strong>biotech capabilities</strong> and C2C adding <strong>design &amp; EPC</strong>, it is creating a <strong>unique ‚Äúdesign-to-water-trial‚Äù model</strong>. The <strong>IPO funding and strong order visibility</strong> support sustainable growth. Long-term EPS could <strong>triple</strong> as the business scales and margins improve.</p>
</blockquote>
</div>
<div id="risks-to-monitor-bear-case" class="section level9">
<p class="heading">‚ùå <strong>Risks to Monitor (Bear Case):</strong></p>
<blockquote>
<p>Execution missteps in M&amp;A, <strong>working capital strain</strong>, or <strong>slower-than-expected adoption</strong> of turnkey model could <strong>weigh on EBITDA and cash flows</strong>. High interest costs may pressure returns in a rising rate environment.</p>
</blockquote>
<hr />
</div>
<div id="final-summary" class="section level9">
<p class="heading">üîë <strong>Final Summary</strong></p>
<table>
<colgroup>
<col width="46%" />
<col width="53%" />
</colgroup>
<thead>
<tr class="header">
<th>Factor</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Growth Trajectory</strong></td>
<td><strong>Strong</strong> ‚Äì 17.4% YoY revenue growth, expanding into biotech and EPC</td>
</tr>
<tr class="even">
<td><strong>Structural Tailwinds</strong></td>
<td>‚úÖ Acquisitions, IPO funding, export pipeline, sector tailwinds</td>
</tr>
<tr class="odd">
<td><strong>Headwinds</strong></td>
<td>‚ö†Ô∏è Margin pressure, working capital intensity, lagging fund deployment</td>
</tr>
<tr class="even">
<td><strong>Growth Prospects</strong></td>
<td><strong>High</strong> ‚Äì potential to become 3‚Äì5x larger over 3‚Äì5 years</td>
</tr>
<tr class="odd">
<td><strong>Key Risks</strong></td>
<td>Integration, leverage, execution, project lumpiness</td>
</tr>
<tr class="even">
<td><strong>Sentiment</strong></td>
<td><strong>Positive</strong> ‚Äì management is proactive, transparent, and ambitious</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="recommendation-for-investors" class="section level9">
<p class="heading">üìå <strong>Recommendation (for Investors):</strong></p>
<ul>
<li><strong>Long-term investors</strong>: <strong>Accumulate on dips</strong>. SGLTL is building a <strong>compounding machine</strong> through strategic M&amp;A and integration.<br />
</li>
<li><strong>Short-term traders</strong>: Be cautious around earnings if <strong>weak margins or cash flow persists</strong>.<br />
</li>
<li><strong>Watch triggers</strong>:
<ul>
<li>Completion of <strong>C2C acquisition</strong><br />
</li>
<li>Quarterly improvement in <strong>cash from operations</strong><br />
</li>
<li>Progress in <strong>utilization of IPO funds</strong><br />
</li>
<li>Execution of <strong>export orders in Q3‚ÄìQ4 FY26</strong></li>
</ul></li>
</ul>
<blockquote>
<p><strong>Target Rationale</strong>: Once integration stabilizes, <strong>PAT could reach ‚Çπ80‚Äì100 Cr/year</strong>, justifying significant re-rating from current levels (assuming continued growth and margin expansion).</p>
</blockquote>
<hr />
<p><strong>Disclaimer:</strong> This analysis is based on public disclosures up to November 26, 2025. Prospective investors should conduct independent due diligence and consult financial advisors.</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
